US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments
2024年5月9日 - 10:31PM
Even as the incidence of Parkinson’s disease (PD) continues to
increase with 90,000 new diagnoses each year1 in the US, the
treatment landscape has remained relatively stagnant. Yet,
neurologists are hopeful about new ways to deliver
levodopa/carbidopa (the current standard of care), new symptomatic
treatments, and potential pathways for future disease modifying
treatments (DMTs).
In the newly published Special Topix™: Novel Treatments in
Parkinson’s Disease: What’s Next in PD After
Carbidopa/Levodopa?, Spherix sought to uncover clinical trial
endpoints and product profiles that most resonate with treating
neurologists.
In the near future, neurologists are interested in novel
delivery mechanisms such as AbbVie’s Produodopa (a subcutaneous
levodopa/carbidopa pump) and symptomatic treatments such as Cerevel
Therapeutics’ tavapadon, meant to reduce the amount of
“side-effect” time PD patients experience with levodopa/carbidopa.
Beyond these two anticipated products, one-half of neurologists
believe in the possibility of an effective DMT within the next five
years. Among those who are more optimistic, one neurologist
stated:
“As a greater understanding of the pathophysiology of PD
progresses, I am hopeful that an effective disease modifying
therapy will become available for PD.”
Neurologists are most hopeful for gene and stem cell therapies
to be truly disease modifying, with nearly 40% of respondents
believing that these modalities hold the greatest promise to
finally change the disease course and lives of PD patients. Such
developmental targets are in the early stages of clinical research
by industry leaders such as Eli Lilly (GBA1 gene therapy), Denali
Therapeutics (AAV vector program), Novo Nordisk (stem cells), and
Roche (biologic prasinezumab).
To understand how neurologists would evaluate potential future
treatments, Spherix conducted an advanced analysis considering
neurologists’ preferences for different modalities, efficacy
levels, routes of administration (such as IV infusion, oral, etc.),
disease phases, and risk levels of adverse events.
Surprisingly, the results show that the route of administration
carries nearly as much weight as efficacy when neurologists
evaluate likely utility of future therapies. Having this knowledge
will be critical to pharmaceutical companies as they think about
how to increase neurologist comfort with the developmental PD
therapies. Hypothetical ideal treatment combinations and
worst-case scenario analysis are also presented in the report.
Neurologist’s interest in pipeline assets that are closer to
approval is also covered. These assets include Annovis Bio’s
buntanetap, Biogen/Denali’s BIIB122/DNL151, NeuroDerm’s ND0612, Sun
Pharma Advance’s vodobatinib, and UCB Pharma/Novartis
minzasolmin.
Special Topix™ is an independent service that includes
access to a report or series of reports based on current events or
topics of interest in specialty markets covered by Spherix.
Spherix Global Insights Spherix is a leading
independent market intelligence and advisory firm that delivers
commercial value to the global life sciences industry, across the
brand lifecycle.
The seasoned team of Spherix experts provides an unbiased and
holistic view of the landscape within rapidly evolving specialty
markets, including dermatology, gastroenterology, rheumatology,
nephrology, neurology, and ophthalmology. Spherix clients stay
ahead of the curve with the perspective of the extensive Spherix
Physician Community.
As a trusted advisor and industry thought leader, Spherix’s
unparalleled market insights and advisory services empower clients
to make better decisions and unlock opportunities for growth.
To learn more about Spherix Global Insights,
visit spherixglobalinsights.com or connect
through LinkedIn.
For more details on Spherix’s primary market research reports
and interactive dashboard offerings, visit or register
here: https://clientportal.spherixglobalinsights.com
NOTICE: All company, brand or product names in this press
release are trademarks of their respective holders. The findings
and opinions expressed within are based on Spherix Global Insight’s
analysis and do not imply a relationship with or endorse.
1 New Study Shows the Incidence of Parkinson’s Disease in the
U.S. is 50% Higher than Previous Estimates | Parkinson's
Foundation
Blaine Cloud, Ph.D., Neurology Franchise Head
Spherix Global Insights
4848794284
blaine.cloud@spherixglobalinsights.com